Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. The company is headquartered in Wilmington, Delaware and currently employs 131 full-time employees. The company went IPO on 2020-09-25. The company has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT7732. PRT3789 is a highly selective degrader of SMARCA2 protein, which, along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT2527 is designed to be a potent and selective CDK9 inhibitor that has the potential to avoid off-target toxicities observed with other less selective CDK9 inhibitor. PRT7732 is a highly selective and orally bioavailable SMARCA2 degrader.
Follow-Up Questions
¿Quién es el CEO de Prelude Therapeutics Inc?
Dr. Krishna Vaddi es el Chief Executive Officer de Prelude Therapeutics Inc, se unió a la empresa desde 2016.
¿Qué tal es el rendimiento del precio de la acción PRLD?
El precio actual de PRLD es de $1, ha decreased un 0.86% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Prelude Therapeutics Inc?
Prelude Therapeutics Inc pertenece a la industria Biotechnology y el sector es Health Care
¿Cuál es la capitalización bursátil de Prelude Therapeutics Inc?
La capitalización bursátil actual de Prelude Therapeutics Inc es $56.6M
¿Es Prelude Therapeutics Inc una compra, una venta o una posición de mantener?
Según los analistas de Wall Street, 6 analistas han realizado calificaciones de análisis para Prelude Therapeutics Inc, incluyendo 3 fuerte compra, 5 compra, 1 mantener, 1 venta, y 3 fuerte venta
